LUCD News & Events

Reports Q4 revenue $1.5M vs. $1.2B last year. Lucid had cash and cash equivalents of $34.7M as of December 31, 2025 vs. $22.4M as of December 31, 2024. "Throughout 2025, we established a strong commercial foundation for EsoGuard, demonstrating that we can consistently generate and sustain demand, drive physician adoption, and engage effectively with both health systems and commercial payors," said CEO Lishan Aklog. "As we move into 2026, our focus is on building on that foundation by converting demand into revenue, with priorities including deepening our relationship with the VA, expanding adoption across health systems, advancing coverage with commercial payors, and securing Medicare coverage, which we still expect in the near-term."

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced that it has been awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually. The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing for EsoGuard that matches the established Medicare payment rate determined by the Centers for Medicare & Medicaid Services, enabling VA hospitals and healthcare facilities nationwide to access EsoGuard through a single, national VA procurement framework.

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced new data from the largest reported real-world experience of non-endoscopic esophageal precancer detection, which evaluated its EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device. The manuscript is currently available on the health sciences preprint server, medRxiv, while undergoing peer review for publication. The study authors concluded that "the largest real-world experience of EsoGuard and EsoCheck to date" demonstrates "excellent safety, tolerability, and scalability... supporting its utility as a non-invasive BE screening tool." The 18-month retrospective analysis evaluated 11,991 at-risk patients who underwent EsoCheck cell collection and EsoGuard testing in routine clinical practice between January 2023 and June 2024. EsoCheck demonstrated a 95% technical success rate, with 95% of procedures completed in under two minutes and no serious adverse events. The vast majority of patients met U.S. gastroenterology society guideline criteria for BE screening, reflecting appropriate physician use of EsoGuard in routine practice.